Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-041992
Filing Date
2025-03-19
Accepted
2025-03-19 16:08:15
Documents
19
Period of Report
2025-03-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A atyr-20250319.htm   iXBRL DEF 14A 1510887
2 GRAPHIC img41052685_0.jpg GRAPHIC 7986
3 GRAPHIC img41052685_1.jpg GRAPHIC 53811
4 GRAPHIC img41052685_2.jpg GRAPHIC 57291
5 GRAPHIC img41052685_3.jpg GRAPHIC 7986
6 GRAPHIC img41052685_4.jpg GRAPHIC 1369509
7 GRAPHIC img41052685_5.jpg GRAPHIC 425925
  Complete submission text file 0000950170-25-041992.txt   6452402

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20250319.xsd EX-101.SCH 7935
21 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20250319_htm.xml XML 123302
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37378 | Film No.: 25752747
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)